- Home
- LSB vs CALC Comparison
LSB vs CALC Comparison
Compare LSB & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSB
- CALC
- Stock Information
- Founded
- LSB 2002
- CALC 2011
- Country
- LSB China
- CALC United States
- Employees
- LSB N/A
- CALC N/A
- Industry
- LSB
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- LSB
- CALC Health Care
- Exchange
- LSB NYSE
- CALC Nasdaq
- Market Cap
- LSB 22.3M
- CALC 26.7M
- IPO Year
- LSB N/A
- CALC N/A
- Fundamental
- Price
- LSB $1.00
- CALC $1.68
- Analyst Decision
- LSB
- CALC Strong Buy
- Analyst Count
- LSB 0
- CALC 3
- Target Price
- LSB N/A
- CALC $16.33
- AVG Volume (30 Days)
- LSB 13.8K
- CALC 24.2K
- Earning Date
- LSB 06-21-2025
- CALC 05-14-2025
- Dividend Yield
- LSB N/A
- CALC N/A
- EPS Growth
- LSB N/A
- CALC N/A
- EPS
- LSB N/A
- CALC N/A
- Revenue
- LSB $79,415,311.00
- CALC N/A
- Revenue This Year
- LSB $39.33
- CALC N/A
- Revenue Next Year
- LSB $75.61
- CALC N/A
- P/E Ratio
- LSB N/A
- CALC N/A
- Revenue Growth
- LSB N/A
- CALC N/A
- 52 Week Low
- LSB $0.36
- CALC $1.43
- 52 Week High
- LSB $6.82
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- LSB 30.09
- CALC 43.11
- Support Level
- LSB $0.99
- CALC $1.61
- Resistance Level
- LSB $1.09
- CALC $1.73
- Average True Range (ATR)
- LSB 0.07
- CALC 0.10
- MACD
- LSB 0.02
- CALC -0.02
- Stochastic Oscillator
- LSB 27.81
- CALC 16.26
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.